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Abstract
The tissue protective functions of the hematopoietic growth factor erythropoietin (EPO) are
independent of its action on erythropoiesis. EPO and its receptors (EPOR) are expressed in
multiple brain cells during brain development and upregulated in the adult brain after injury.
Peripherally administered EPO crosses the blood-brain barrier and activates in the brain anti-
apoptotic, anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular
endothelial cells and stimulates angiogenesis and neurogenesis. These mechanisms underlie its
potent tissue protective effects in experimental models of stroke, cerebral hemorrhage, traumatic
brain injury, neuroinflammatory and neurodegenerative disease. The preclinical data in support of
the use of EPO in brain disease have already been translated to first clinical pilot studies with
encouraging results with the use of EPO as a neuroprotective agent.
The cytokine erythropoetin (EPO)
The cytokine erythropoietin (EPO) is a 34 kD glycopro-
tein which was originally described to stimulate erythro-
poiesis. EPO supports the proliferation and
differentiation of erythroid progenitor cells and is critical
for their survival [1]. The main site of EPO production is
fetal liver and adult kidney [1]. Mice deficient for EPO or
EPO receptor (EPOR) genes die at embryonic day 13
(E13) because of severe anemia caused by deficiency in
definitive erythropoiesis [2-4]. Over the last decade it has
become clear that EPO acts as growth and survival factors
for multiple tissues expressing the EPO receptor [1]. The
number of described targets of EPO action continues to
grow.
EPO Receptor (EPOR)
EPO acts by binding to its specific transmembrane recep-
tor (EPOR). EPOR belongs to the single-chain cytokine
type I receptor family [5]. These receptors are character-
ized by an extracellular N-terminal domain with con-
served cysteines and a WSXWS-motif, a single
hydrophobic transmembrane segment and a cytosolic
domain with no intrinsic kinase activity [5]. Two trans-
membrane EPOR molecules form a homodimer that
binds one EPO molecule leading to a conformational
change and tight bonding of the two EPOR monomers
which in turn activate two Janus family tyrosine kinase 2
(JAK2) molecules which associate with cytoplasmic
domain of the EPOR. Once activated, JAK2 phosphor-
ylates distal parts of receptors which subsequently serve as
docking sites for downstream signaling molecules. Multi-
ple signal transduction pathways are activated down-
stream of EPOR/JAK2 [1,5]. In neurons these include
signal transducers and activators of transcription (Stat),
phosphatidylinositol 3-kinase (PI3K)/Akt, Ras/extracellu-
lar signal regulated kinase (ERK1/2), nuclear factor-
kappa-B (NF-κB), and calcium [6-8]. Best investigated
from these are PI3K/Akt and Ras-MAPK pathways, both of
which are important for the antiapoptotic and trophic
effects of EPO [8-18]. NFκB pathway plays a role in antia-
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poptotic activity of EPO in neurons [7,19,20] as well as in
EPO-mediated propagation of neural stem cells [21]. In
addition EPO by activating phospholipase Cγ modulates
intracellular calcium concentration, electrical activity and
neurotransmitter release in PC12 cells [22-24] as well as
in hippocampal neurons and brain slices [25,26]. The role
of the Stat transcriptional factors in regard to EPO effects
in the neural cells remains unclear; EPO induces phos-
phorylation of Stat5 in neurons [8,19,27], neural stem
cells [21] and neuroblastoma cells [17,28]. Using primary
hippocampal neurons from Stat5a/b knock-out mice we
have recently shown that the presence of functional Stat5
is required for the trophic but not for the protective effect
of EPO against glutamate-induced toxicity [9].
EPO signaling is terminated by activation of phosphatases
which dephosphorylate JAK2. The ligand-receptor com-
plex is then internalized and degraded by the proteasome
[1,5]. In hematopoietic cell lines 60% of the internalized
EPO is re-secreted [29].
The brain EPO/EPOR system
mRNA and protein of EPO and EPOR are detected in
brain (hippocampus, internal capsule, cortex, midbrain),
as well as in vitro in neurons, astrocytes, oligodendrocytes,
microglia and cerebral endothelial cells [24,30-44] sug-
gesting that this factor can function in the brain in a para-
crine and/or autocrine manner. In the developing mouse
brain expression of EPO and EPOR peaks during midges-
tation and decreases to adult levels in late gestation [43].
Brain specific ablation of EPOR leads to deficits in neural
cell proliferation and neuronal survival in the embryonic
brain and in post-stroke neurogenesis in the adult brain
[45,46]. Expression of EPO and EPOR in the adult brain is
stress-responsive and is regulated by oxygen supply: Both
receptor and ligand expression is upregulated after
hypoxia or ischemia [36,42,43,47-50]. Other stimuli such
as hypoglycemia, insulin release, reactive oxygen species
and insulin-like growth factor activate hypoxia-inducible
factor and lead to increased expression of EPO [51,52].
Proinflammatory cytokines downregulate expression of
EPO mRNA but increase that of EPOR in astrocytes [34].
Based on the loss of some of the tissue protective effects of
EPO and its non-hematopoietic derivative, the car-
bamylated EPO (CEPO) in mice lacking the common β
chain shared by the members of the IL-3 receptor family,
Brines and Cerami have proposed that the cytoprotective
effects of EPO and CEPO are mediated by a heteromeric
receptor complex comprised of one EPOR subunit and a
dimer of the common β chain [6,53]. Immunoreactivity
of the common β chain has been detected in brain tissue
with a pattern reminiscent to that of the classical EPOR
[53]. Furthermore, the common β chain can be coimmu-
noprecipitated with EPOR antibodies from the P19
embryonal carcinoma cells [53], but the existence of the
proposed heteromeric receptor structure in primary cells
or tissues has yet to be directly proven. In a recent study
no expression of the common β subunit was detected in
neuronal PC-12 cells even if EPO rescued these cells from
staurosporine-induced apoptosis [28]. Interestingly, the
classical EPOR is required for EPO-stimulated neuronal
differentiation and survival but not for neurogenesis
induced by CEPO suggesting that differential receptor
interactions mediate the effects of EPO and CEPO in brain
cells [28,54].
Neuroprotection by EPO is independent of 
hematopoesis
The neuroprotective actions of EPO can be separated from
its hematopoietic actions, a fact that is of value for thera-
peutic applications where the increase in red cell mass is
not desired. EPO and EPO derivatives are directly neuro-
protective in cell culture models (see below) and after
direct application into the brain [36,55,56]. Moreover,
CEPO and other EPO derivatives which do not bind to
EPOR in myeloid cells and thus lack hematopoietic activ-
ity display potent tissue protective activities [57-59].
Expression of EPO and the classical EPOR in brain cells is
induced by hypoxic-ischemic stress and contributes to
ischemic tolerance [14,24,32,37,41,49,50,60-66] while
neutralization of the brain endogenous EPO augments
ischemic damage [56]. Brain-specific genetic ablation of
the classical EPOR impairs post-stroke neurogenesis and
neuronal survival [45,46] whereas transgenic brain spe-
cific overexpression of human EPO is associated with
reductions in postischemic infarct volume, brain swelling
and functional deficits in a transient stroke model [16].
Multimodal neuroprotective profile
EPO has been reported to induce a broad range of cellular
responses in the brain directed to protect and repair tissue
damage (Figure 1). EPO is neuroprotective in a variety of
hypoxic, hypoglycemic, and excitotoxic in vitro models
[7,8,10,14,17,18,20,21,42,45,50,57,67-72]. A fundamen-
tal mechanism of EPO-induced neuroprotection in cul-
tured neurons is its ability to inhibit apoptosis reducing
both DNA damage and cell membrane asymmetry
[7,8,10,14,17,18,20,21,42,45,50,57,67-72]. Necrotic cell
death (for example, after glutamate exposure) is also be
attenuated by EPO [9,69,73]. Why astroglial cultures are
protected by EPO from nitric oxide- and staurosporine-
induced death but not from arsenic trioxide- or glutamate-
induced toxicity is not fully understood [73,74].
Another tissue-protective mechanism of EPO is its ability
to protect cells against oxidative damage [75,76]. EPO
inhibits lipid peroxidation by increasing the activities of
cytosolic antioxidant enzymes such as superoxide dis-
mutase and glutathione peroxidase [77-79].Experimental & Translational Stroke Medicine 2009, 1:4 http://www.etsmjournal.com/content/1/1/4
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EPO attenuates inflammation by reducing reactive astro-
cytosis and microglia activation and by inhibiting
immune cells recruitment into the injured area
[47,58,59,70,80-85]. In cerebrovascular endothelial cell
cultures EPO down-regulates TNF-α-induced gene expres-
sion of interleukin-6 (IL-6), IL-1beta, CXCR4, and IL-
1alpha [86]. It also directly counteracts interferon-γ- and
lipopolyssaccharide-induced cytotoxicity in oligodendro-
cytes, preserves white matter [87] and reduces TNF-α
release and its effects in cultured Schwann cells [88].
EPO protects vascular integrity and stimulates angiogen-
esis [89-92]. It preserves blood-brain barrier integrity dur-
ing injury by restoring expression of tight junction
proteins [90,93,94], by reducing vascular inflammation
[95] and reactive free radical expression [90,93,94,96]. In
vasculogenesis EPO stimulates proliferation of endothe-
lial precursor cells, production of matrix metalloprotein-
ase-2, migration of endothelial cells into vascular sites
and formation of capillary tubes [90-92,97,98]. EPO dis-
plays direct antiapoptotic activity in cerebral endothelial
cells during oxidative stress and ischemic injury as well
[91]. Stimulation of endothelial nitric oxide synthase
(eNOS) activity has been shown to contribute to the
improvements by EPO after experimental cerebral hemor-
rhage [99-101]. Interestingly, plasma and tissue levels of
NO are markedly increased in transgenic rats overexpress-
ing EPO [102] whereas the vascular protection by EPO is
abolished in eNOS-deficient mice [103].
EPO promotes differentiation towards neurons in several
neuroblastoma cell lines, in neural stem cell cultures
derived from both embryonic and adult neuronal germi-
nal zones, as well as in embryonic neural progenitor-cell
cultures [21,45,46,54,89,104-108]. Neuronal differentia-
tion of adult neural progenitor cell by EPO seem to
require activation of the sonic hedgehog signaling and up-
regulation of suppressor of cytokine signaling-2 (SOCS2)
[54,105]. EPO increases proliferation of oligodendrocyte
progenitors and promotes differentiation of oligodendro-
cytes in culture [33,34]. EPOR-/- fetuses exhibit increased
apoptosis in the brain and a reduction in the number of
neural progenitor cells, as well as increased sensitivity to
hypoxia prior to significant anaemia or heart defects in the
embryo proper [42,45,46]. Moreover, adult mice that lack
EPOR in the brain have significantly reduced neurogene-
sis in the subventricular zone and demonstrate impaired
migration of precursors into infracted cortex [46]. Never-
theless, expression of EPO or EPOR on neural cells is not
indispensable for brain development [42,45,46].
The reported neurotrophic effects of EPO include the abil-
ity to stimulate axonal regrowth, neurite formation, den-
dritic sprouting, electrical activity and modulate
intracellular calcium and neurotransmitter synthesis and
release [9,13,22,23,25,26,46,109-113]. A recent study
demonstrated a calcium sensitive activation of cAMP
response element binding protein (CREB) and induction
of brain-derived neurotrophic factor (BDNF) gene expres-
sion by EPO in primary hippocampal neurons [25]. In rat
hippocampal slices, EPO improved synaptic transmission
during and following oxygen and glucose deprivation
[13]. However, it has not been directly shown that EPO
induces formation of new synapses.
Animal Studies
The preclinical data in support of the use of EPO in
human brain disease have explosively increased since the
first discovery of its neuroprotective action. In particular,
the preclinical evidence in support for testing EPO in
human acute ischemic stroke fulfills most of the STAIR cri-
teria [114] such as testing by several laboratories using
both temporary and permanent stroke models, post-treat-
ment at several doses and exploration of therapeutic win-
dow, characterization of pharmacokinetic profile in
respect to blood-brain-barrier penetration after peripheral
administration, measurement of histological and func-
tional outcome with prolonged survival.
Cerebral ischemia
The in vivo potential of EPO to protect neurons against
ischemic neuronal damage was first provided by the Sas-
aki group. Their landmark finding was that application of
recombinant human (rh)EPO directly into the cerebral
Multimodal neuroprotective profile of erythropoietin (EPO) Figure 1
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ventricles of gerbils prevented ischemia-induced learning
disabilities and protected hippocampal pyramidal CA1
neurons from lethal ischemia while neutralization of the
endogenous brain EPO by infusions of soluble EPOR
before a nonlethal mild ischemia induced neuronal death
[56]. Since the circulating EPO, as a large, highly glyco-
sylated negatively charged molecule, was thought not to
cross the blood-brain-barrier [91,115,116], the early stud-
ies used direct intracerebroventricular route of adminis-
tration of EPO to demonstrate its potent tissue protective
activity in focal and global models of cerebral ischemia
[36,55,56]. The first evidence for a neuroprotective effect
of EPO by peripheral route of administration was pro-
vided by Brines et al. (2000) who demonstrated in a focal
stroke model reduction of infarct volumes by intraperito-
neally applied high dose rhEPO (5000 U/kg) up to 6 h
after reperfusion. Immunohistochemical detection of
biotinylated rhEPO 5 hours after its intraperitoneal injec-
tion at the therapeutically effective dose (5000 U/kg) fur-
ther provided evidence that EPO can cross the blood-
brain barrier [117]. Studies in several species including
man have confirmed the ability for high dose EPO to cross
the blood-brain barrier in therapeutic effective concentra-
tions [118-122]. To date EPO and its derivatives have
shown to reduce histological damage and improve func-
tional outcome when given as intraperitoneal or even
intranasal post-treatment after experimental stroke [57-
59,70,85,89,123], global cerebral ischemia [124], neona-
tal stroke and hypoxia-ischemia [107,125-128]. For exam-
ple, a comprehensive dosing study using post-treatment
with EPO and CEPO starting at 6 h after an embolic mid-
dle cerebral artery occlusion in rats demonstrated reduc-
tion of functional deficits and infarct volume up to 28
days models of middle cerebral artery occlusion [59].
Induction of EPO and its intracellular signaling interme-
diates represents a significant component of tolerance
induced by ischemic or hypoxic preconditioning [60-
62,65]. Here activation of the antiapoptotic and anti-
inflammatory signaling seems to play a major role in the
EPO-induced neuroprotection [14,19,129].
Cerebral hemorrhage
Post-treatment with EPO starting at 2 h after induction of
intracerebral hemorrhage (ICH) by intraparenchymal
injections of collagenase or autologous blood dose-
dependently reduced volume of hemorrhage, brain
edema, perihematomal apoptosis and inflammation in a
rat model [99]. Functional recovery was faster and more
efficient in the EPO-treated group and was associated with
reduction in hemispheric brain atrophy 5 weeks after the
induction of ICH [99]. Cerebral vasospasm and ischemic
brain damage after subarachnoid hemorrhage (SAH) by
autologous blood injections into the cisterna magna in
rabbits are reduced by EPO administered either by intra-
peritoneal injections of rhEPO or by delivery of adenovi-
ral vectors encoding the human EPO into cisterna magna
immediately after induction of SAH [130-133]. Mortality
and functional deficits 3 days after induction of SAH were
reduced in EPO treated rabbits [130-132]. In a rat model
of SAH, the impaired autoregulatory response of cerebral
blood flow to intravenous noradrenaline was restored by
a single subcutaneous bolus of EPO [134].
Traumatic brain and spinal cord injury
Administration of EPO and EPO-analogs in experimental
models of traumatic brain and spinal cord injury leads to
morphological, functional and cognitive recovery that can
be attributed to a multitude of cytoprotective mechanisms
including inhibition of apoptosis, anti-inflammatory and
anti-oxidant actions, restoration of blood-brain barrier
integrity, stimulation of neurogenesis and angiogenesis
[67,95,96,104,117,135-146]. Induction of EPO and its
protective down stream signaling via Akt seems also to
account for the protective effect of heat acclimation stress
in a closed head injury model [147,148]. Brain edema
after experimental brain injury can effectively be attenu-
ated by post-treatment with EPO [95,138,140]. A reduc-
tion of cytotoxic and vasogenic edema may be anticipated
based on the direct actions of EPO on glutamate release
[112] and on the endothelial barrier function (see above).
It is not clear to date which from the panoply of neu-
rorestorative effects of EPO are responsible for the long-
term prevention of trauma-induced brain atrophy, cogni-
tive and neurobehavioral dysfunction [104,135-137,146].
In this context it is interesting to note that chronic periph-
eral administration of EPO has been reported to improve
spatial memory function and cognitive functioning in the
context of an aversion task also in healthy mice [119,149].
Improved hippocampal functioning after a single intrave-
nous bolus of EPO was recently shown in a study using
functional magnetic resonance imaging in healthy human
volunteers [150].
Degeneration & neuroinflammation
EPO and its analogs offer protection also in models of
neurodegenerative and neuroinflammatory disease. In
experimental autoimmunencephalitis (EAE), an animal
model for multiple sclerosis (MS), treatment with EPO
and EPO analogs can improve functional recovery, reduce
tissue damage, inflammatory responses and blood-brain
barrier leakage [47,80-84,117]. Beneficial effects of EPO
have also been reported in models of peripheral axonal
nerve injury, injury-induced Wallerian degeneration and
HIV-associated sensory neuropathy [88,151,152]. Here,
the anti-cytokine, anti-apoptotic, anti-oxidative and
trophic effects on both neurons and oligodendrocyte pro-
genitor cells by EPO seem to play an important role in
reducing inflammation and preserving myelination and
neuronal function [35,47,80-84,86-88,151].Experimental & Translational Stroke Medicine 2009, 1:4 http://www.etsmjournal.com/content/1/1/4
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Chronic neurodegeneration might also be a target for EPO
therapy as EPO and its analogs can counteract degenera-
tive processes in experimental models of Parkinson dis-
ease and amyotrophic lateral sclerosis (ALS) by inducing
anti-oxidant enzymes, inhibiting apoptosis and stimulat-
ing axonal regeneration [78,153-155]. EPO improved
graft survival of embryonic ventral mesencephalic
dopamine neurons when transplanted into the striatum
of 6-hydroxy-dopamine lesioned rats [156]. However, not
all degenerative diseases seem to respond to EPO therapy
[157].
Translation to human brain disease
EPO and its receptor are abundantly expressed in the
developing human brain decreasing to a weak constitutive
expression in the adult [30,39,41,66,119,158]. Hypoxia
rapidly induces expression of brain EPO as evidenced by
the increased expression of EPO in cerebrospinal fluid
(CSF) or postmortem brain tissue in humans with trau-
matic brain injury, SAH, stroke and hypoxia
[31,41,66,121,159,160]. Expression of EPOR has also
been detected on myelin sheath of radicular nerves and in
the epineurial blood vessels of sural nerves in the human
peripheral nervous system [161,162]. Measurements of
endogenous levels of EPO in CSF of patients with neuro-
degenerative diseases has revealed EPO in CSF of patients
with ALS to be lower than in controls whereas patients
with Alzheimer disease (AD) or vascular dementia had
EPO levels comparable to control persons [163,164].
Astrocytic EPOR immunoreactivity in postmortem hip-
pocampus and temporal cortex from subjects with AD or
chronic schizophrenia has been reported to be increased
as compared to age-matched control brains [119,158]. In
AD, however, no association of EPOR-positive astrocytes
was found with summary measures of global cognition or
AD pathology [158].
Millions of patients have already been receiving EPO as a
highly efficacious and safe treatment for anemia [1].
Indeed, the first proof-of-concept study on use of EPO in
human acute ischemic stroke has already demonstrated
that treatment of stroke patients with intravenous high
dose EPO is not only well tolerated but is associated with
improvement in clinical outcome at 30 days [120].
Encouraging results with the use of EPO as a neuroprotec-
tive agent have been recently reported in clinical pilot
studies after out-of-hospital cardiac arrest [165], ureamia-
associated peripheral neuropathy [166], chronic schizo-
phrenia [167] and MS [145]. A small pilot study to probe
the safety and efficacy of EPO in SAH was recently prelim-
inarily terminated with no conclusive results because of
low recruitment rate [168]. To date a randomized multi-
center double blinded placebo-controlled clinical trial in
acute ischemic stroke is running (for details see http://
www.epo-study.de) reflecting the beginning of explora-
tion of EPO and its analogs for clinical neuroprotection in
large phase II/III setting.
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